Genmab A/S - American Depositary Shares (GMAB) Covered Calls
You can sell covered calls on Genmab A/S - American Depositary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GMAB (prices last updated Thu 11:00 AM ET):
Genmab A/S - American Depositary Shares (GMAB) Stock Quote | ||||||
---|---|---|---|---|---|---|
Last | Change | Bid | Ask | Volume | P/E | Market Cap |
20.91 | -0.64 | 20.90 | 20.91 | 313K | - | 0.8 |
Covered Calls For Genmab A/S - American Depositary Shares (GMAB) | ||||||
---|---|---|---|---|---|---|
Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
Dec 20 | 20 | 0.00 | 20.91 | -4.4% | -178.4% | |
Jan 17 | 20 | 0.00 | 20.91 | -4.4% | -43.4% | |
Subscribers get access to the full covered call chain, and more features. |
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Top 10 Open Interest For Dec 20 Expiration | Top 5 High Yield | |||||
---|---|---|---|---|---|---|
1. | NVDA covered calls | 6. | IWM covered calls | 1. | QUBT covered calls | |
2. | SPY covered calls | 7. | QQQ covered calls | 2. | NNE covered calls | |
3. | FXI covered calls | 8. | KWEB covered calls | 3. | WULF covered calls | |
4. | XLF covered calls | 9. | TLT covered calls | 4. | LRMR covered calls | |
5. | EEM covered calls | 10. | EWZ covered calls | 5. | ACHR covered calls |
Want more examples? GM Covered Calls | GME Covered Calls